FIMAN Named to the “Future 100 · Top 100 Enterprises for the Future of Skin Health” List!

From November 27-29, the SIA (Scientific-skincare Innovation Alliance) 2025 Annual Conference was grandly held in Shanghai, where it officially released the “Future Skin Science Conference and the Future 100 · Top 100 Enterprises for the Future of Skin Health” list. Feiman Bio (FIMAN) was honored with a place on the list, being named a “2025 Medical Aesthetics Technology Company”! The judging panel for the “Future 100 · Top 100 Enterprises for the Future of Skin Health” list is composed of the [SIA Skin Health Sci-Tech Investor Alliance], which brings together over 30 leading investment institutions, and the [SIA Think Tank of 100], which features nearly 200 global authoritative experts. The panel systematically identifies innovative enterprises with high growth potential and investment value in niche sectors such as medical aesthetics technology and biotechnology, selecting high-potential “hidden champions” in the industry from an authoritative perspective. FIMAN stood out for its core technological innovation and high growth, earning its place on the “Future 100” list and becoming a model for future enterprises that possess both innovative depth and growth potential. Ms. Zhao Qing, Deputy General Manager of FIMAN, was invited to participate in the conference’s special session, a roundtable forum titled “Ending the Light-Traffic Model: Insights from the ‘Weight’ Rule of Trust in Cosmeceutical-Device Synergy.” She shared profound insights on building a healthy development ecosystem in the collagen sector—safeguarding the aesthetic experience with quality and winning the “weight” of trust with safe and effective products.

Ms. Zhao Qing stated that FIMAN has always followed a “heavy” model. This includes continuously hosting medical aesthetic doctor case competitions, heavily investing in physician education, building the industry’s first medical-grade bovine source industrial base in Northeast China, and its long-term commitment to the field of animal-derived collagen. The core logic is that competition in the beauty and health industry is essentially a battle for trust. From the perspective of trust, the “weight” principle holds irreplaceable long-term value.

Looking ahead, FIMAN will continue to be rooted in evidence-based medicine, lead breakthroughs with innovation, establish an industry benchmark as a “National-Quality Collagen,” and drive the high-quality transformation of China’s biotechnology sector!